Back to Search
Start Over
Continuing cabazitaxel beyond 10 cycles for metastatic castrate-resistant prostate cancer: is there a benefit?
- Source :
- Eur J Hosp Pharm
- Publication Year :
- 2019
- Publisher :
- BMJ, 2019.
-
Abstract
- Aim Cabazitaxel prolongs survival in patients with metastatic castration-resistant prostate cancer in the postdocetaxel setting. We investigate the benefit of continuing cabazitaxel beyond 10 cycles in patients who are clinically responding without significant toxicity. Methods A comparison was made between patients who received cabazitaxel for >10 cycles and those who had ≤10 cycles. Overall survival (OS), prostate-specific antigen (PSA) response, alkaline phosphatase (ALP) changes and treatment-associated adverse events were evaluated. Results The median OS was 9 months (range 0.75–59), with OS significantly higher in patients who received extended duration of treatment: 14 months (range 3–90) vs 7 months (range 1.3–21) in patients treated with 4–10 cycles (HR 0.28, 95% CI 0.1 to 0.74, p=0.01). PSA decline did not show a significant correlation with OS (PSA decline ≥50%, p=0.54). Furthermore, there was no significant difference in OS between patients who had a normal versus high ALP at baseline. There was no clear evidence of cumulative toxicity in those having >10 cycles. Conclusion A substantial proportion of patients with metastatic castration-resistant prostate cancer were able to receive more than 10 cycles of cabazitaxel without clinically relevant cumulative toxicity.
- Subjects :
- Male
Oncology
medicine.medical_specialty
Castrate-resistant prostate cancer
030226 pharmacology & pharmacy
03 medical and health sciences
Prostate cancer
0302 clinical medicine
Internal medicine
medicine
Humans
030212 general & internal medicine
General Pharmacology, Toxicology and Pharmaceutics
Adverse effect
Original Research
Cumulative toxicity
Taxane
business.industry
Significant difference
Prostate-Specific Antigen
medicine.disease
Prostatic Neoplasms, Castration-Resistant
Treatment Outcome
Cabazitaxel
Toxicity
Taxoids
business
medicine.drug
Subjects
Details
- ISSN :
- 20479964 and 20479956
- Volume :
- 28
- Database :
- OpenAIRE
- Journal :
- European Journal of Hospital Pharmacy
- Accession number :
- edsair.doi.dedup.....9b98fee3670211bf47b1b7ffef34f2e7